ETHICS AND SUSTAINABILITY: ELICITING MILLENNIAL PERSPECTIVES ON THE ETHICS WITHIN PHARMACEUTICALS
Abstract
Americans spend $392 billion in prescribed medication per Washington post; Wall Street Journal study compared branded rugs in Ontario, Canada, England, Norway the findings confirmed that United States prices were higher prices than Norway; and England. United States with the highest prices contribute to price gouging? EpiPen by Mylan from $2 overseas and $750; Daraprim by Turning Pharmaceuticals gouge from $13.50 to $750 per pill; and Cosmegen $20 to $30 overseas and $1400 per injection these prices are horrendous especially when the drugs are required for debilitating diseases. Ebola scare in 2014 required protective devices against contamination of the virus. Kimberly Clark and Halyard Health manufactured, marketed, and sold Microcool gowns with a 77% failure rate as confirmed by Intertek Labs. What contributes to the pharmaceutical unethical conduct that includes price gouging and exploitation? Pharmaceuticals growing with an emphasis on buying rights to drugs and drastically increasing the cost of drugs and medical devices without substitutes ethical; what do millennials who are projected by Fortune to dominate the workforce by 2020 think on ethics within pharmaceuticals? The findings confirmed that the pharmaceuticals price gouging, sale of drugs and products that are later recalled, and huge budgets in marketing instead of R&D weren’t ethical and results confirmed that the pharmaceutical companies should focus on their core which is saving patients’ lives.
JEL: L60, L65, I18 A14, L29, K32, M14
Article visualizations:
Keywords
References
Alexander, H. (2014).What is the Ebola virus? (Accessed July 30, 2017) Retrieved from www.telegraph.co.uk
Alpern, J. D.; & Klugman, C. M. (2016). Drastic surge in drug prices: ‘Unethical and immoral’. (Accessed May 17, 2017) Retrieved from www.ahcmedia.com
Avenatti, E. (2017). Jury hits Kimberly-Clark and Halyard Health with $454 million fraud verdit over sale of defective medical devices announces Eagan Avenatti, LLP. (Accessed May 17, 2017) Retrieved from www.businesswire.com
Benson, J. A. (1988). Crisis revisited: An analysis of strategies used by Tylenol in the second tampering episode. Communication Studies, 39(1), 49-66. (Accessed May 17, 2017) Retrieved from www.tandonline.com
Celona, T. (2011). McNeil recalls add up to $900 million loss for J&J. (Accessed May 27, 2017) Retrieved from www.montromerynews.com
Center for Disease Control (2016). 2014 Ebola outbreak in West Africa – case counts. (Accessed May 17, 2017) Retrieved from www.cdc.gov
Copeland, R. & Matthews, C. M. & Viswanatha, A. (2015). Turing pharmaceutical replaces Martin Shkreli as CEO. (Accessed May 17, 2017) Retrieved from www.wsj.com
Cooper, A. (2016). 60 minutes investigates medical gear sold during Ebola crisis. (Accessed May 27, 2017) Retrieved from www.cbsnews.com
Creswell, J. & Pollack, A. (2015). Martin Shkreli, the bad boy of pharmaceuticals, hits back. (Accessed May 17, 2017) Retrieved from www.nytimes.com
Densford, F. (2016). Halyard battles ’60 minute’s story on faulty Ebola gowns. (Accessed May 27, 2017) Retrieved from www.massdevice.com
Dorfman, J. (2016). Price gouging laws are good politics but bad economics. (Accessed May 17, 2017) Retrieved from www.forbes.com
Droppert, H., & Bennett, S. (2015). Corporate social responsibility in global health: an exploratory study of multinational pharmaceutical firms. Globalization and Health, 11, 15. (Accessed May 17, 2017) doi.org/10.1186/s12992-015-0100-5
Honig, S. (2016). Manufacturer communication regarding unapproved uses of approved or cleared medical products. (Accessed May 17, 2017) Retrieved from www.fda.gov
Fox News (2015). Maker of children’s Tylenol to plead guilty over recall. (Accessed May 10, 2017) Retrieved from www.foxnews.com
Franceso, C., Bakhordarian, A., Thames, A. D., Du, A. M, Jan, A. L., Nahcivan, M., Nguyen, M. T., Sama, N., Manfrini, E., Francesco, P., Rocha, M. R., & Maida, C. A. (2015). Ebola: translational science considerations. (Accessed July 30, 2017) doi:10.1186/s12967-014-0362-3. Retrieved from www.ncbi.nlm.nih.gov
Frizell, S. (2015) Tylenol maker admits selling liquid medicine contaminated with metal. (Accessed May 11, 2017) Retrieved from www.time.com
Garde, D. (2016). The EpiPen was her ‘baby.’ Now this pharma CEO is in the hot seat over price hikes. (Accessed May 11, 2017) Retrieved from www.statnews.com
Gmoser, J. & Feloni, R. (2016). Richard Branson: Entrepreneurs need to fill the gap where the government is lacking. (Accessed May 11, 2017) Retrieved from www.businessinsider.com
Hollie, P. G. (1983). Making products tamper-resistant. (Accessed May 26, 2017) Retrieved from www.nytimes.com
Hopkins, J. S. (2016). Mylan profit misses estimates as EpiPen sales decline. (Accessed May 17, 2017) Retrieved from www.bloomsberg.com
Hyder, S. (2016). Millennials and shopping: how retailers are missing the mark. (Accessed May 17, 2017) Retrieved from www.forbes.com
Jamerson, J (2016). Halyard denies ’60 minutes’ allegations it sold defective Ebola protection. (Accessed May 17, 2017) Retrieved from www.wsj.com
Kaplan, T. (2005). The Tylenol crisis: How effective public relations saved Johnson & Johnson. (Accessed May 17, 2017) Retrieved from www.nytimes.com
Kavilanz, P. (2011). U.S. takes over three Tylenol plants. (Accessed May 11, 2017) Retrieved from www.money.cnn.com
Kessel, M. Restoring the pharmaceutical industry’s reputation. (Accessed May 11, 2017) Retrieved from www.nature.com
Lazonick, W. (2014). Profits without prosperity. (Accessed May 17, 2017) Retrieved from www.hbr.org
LoGiurato, B. (2016). The Epipen pricing-surge scandal brings out the worst parts of our government healthcare. (Accessed May 11, 2017) Retrieved from www.businessinsider.com
Long, H. (2016). Here’s what happened to AIDS drug that spiked 5,000%. (Accessed May 11, 2017) Retrieved from www.money.cnn.com
Lorenzetti, L. (2015). Here’s why Turing Pharmaceutical says 5,000% price bump is necessary. (Accessed May 17, 2017) Retrieved from www.fortune.com
Nicks, D (2015). This is why the U.S. pays more for prescription than other countries. (Accessed May 11, 2017) Retrieved from www.time.com
Nieweler, A. (2016). Big pharma: Corruption and unethical practices. (Accessed May 14, 2017) Retrieved from www.whistleblowersecurity.com
Omoleke, S. A., Mohammed, I., & Saidu, Y. (2016). Ebola viral disease in West Africa: A threat to global health, economy and political stability. (Accessed July 30, 2017) doi:10.4081/jphia.2016.534. Retrieved from www.ncbi.nlm.nih.gov
Paine, L. S. (1994). Managing for organizational integrity. (Accessed May 14, 2017) Retrieved from www.hbr.org
Pollack, A. (2015). Martin Shkreli resigns from Turing pharmaceuticals. (Accessed May 11, 2017) Retrieved from www.nytimes.com
Ramsey, L. (2016, February 04). Martin Shkreli’s former company had a $23, 000 yatch party while claiming it was losing money. (Accessed May 17, 2017) Retrieved from www.businessinsider.com
Ramsey, L. (2016, September 20). The EpiPen pricing scandal just got even more complicated for the CEO and her family at heart of it. (Accessed May 12, 2017) Retrieved from www.businessinsider.com
Rehak, J. (2002). Tylenol made a hero of Johnson & Johnson: The recall that started them all. (Accessed May 17, 2017) Retrieved from www.nytimes.com
Reuters (2007, May 13). Merck KGaA sells generic unit to Mylan for $6.6 bln. (Accessed May 17, 2017) Retrieved from www.reuters.com
Reuters, 2015, March 11). Tylenol maker pleads guilty to selling metal-tainted drugs. (Accessed May 11, 2017) Retrieved from www.nydailynes.com
Rubinkam, M. & Dale, M. (2015). Make of children’s Tylenol plead guilty over recall for particles in medicine. (Accessed May 13, 2017) Retrieved from www.mcall.com
Russell, J. (2016). CNS – Firm accused of selling faulty Ebola gowns. (Accessed May 17, 2017) Retrieved from old www.archives.courthousenews.com
Salari, P., Namazi, H., Abdollahi, M., Khansari, F., Nikfar, S., Larijani, B., & Araminia, B. (2013). Code of ethics for the national pharmaceutical system: Codifying and compilation. Journal of Research in Medical Sciences : The Official Journal of Isfahan University of Medical Sciences, 18(5), 442–448. (Accessed May 11, 2017) Retrieved from www.jrms.ac.ir
Shah, A. (2010). Pharmaceutical corporations and medical research. (Accessed May 16, 2017) Retrieved from www.globalissues.org
Shultz, J. M., Zelde, E., Espinola, M., & Rechkemmer, A. (2017). Distinguishing epidemiological features of the 2013-2016 West Africa Ebola virus disease outbreak. (Accessed July 30, 2017). Doi:10.1080/21665044.2016.1228326. Retrieved from www.ncbi.nlm.gov
Singer, N. & Abelson, R. (2011). Can Johnson & Johnson get its act together. (Accessed May 16, 2017) Retrieved from www.nytimes.com
Swanson, A. (2015). Big Pharmaceutical companies are spending far more on marketing than research. (Accessed May 17, 2017) Retrieved from www.washingonpost.com
The Associated Press. (2011). Johnson & Johnson’s profit falls 12%, hurt by serious recalls. (Accessed May 16, 2017) Retrieved from www.nytimes.com
Timmerman, L. (2015). A timeline of the Turing pharma controversy. (Accessed May 17, 2017) Retrieved from www.forbes.com
Verschoor, C. C. (2016). Pharma companies need fewer unethical practices. (Accessed May 17, 2017) Retrieved from www.sfmagazine.com
Wieczner, J. (2016). What Mylan’s EpiPen cost scandal says about the drug price problem. (Accessed May 17, 2017) Retrieved from www.fortune.com
Weintraub, A. (2016). Mylan CEO Bresch admits ‘full responsibility’ for EpiPen price hikes. (Accessed May 17, 2017) Retrieved from www.forbes.com
World Health Organization (2017). Ebola virus disease. (Accessed May 17, 2017) Retrieved from www.who.int
Wu, T. (2017). How to stop drug price gouging. (Accessed May 17, 2017) Retrieved from www.nytimes.com
DOI: http://dx.doi.org/10.46827/ejefr.v0i0.223
Refbacks
- There are currently no refbacks.
Copyright (c) 2018 Jet Mboga
This work is licensed under a Creative Commons Attribution 4.0 International License.
The research works published in this journal are free to be accessed. They can be shared (copied and redistributed in any medium or format) and\or adapted (remixed, transformed, and built upon the material for any purpose, commercially and\or not commercially) under the following terms: attribution (appropriate credit must be given indicating original authors, research work name and publication name mentioning if changes were made) and without adding additional restrictions (without restricting others from doing anything the actual license permits). Authors retain the full copyright of their published research works and cannot revoke these freedoms as long as the license terms are followed.
Copyright © 2016 - 2023. European Journal of Economic and Financial Research (ISSN 2501-9430) is a registered trademark of Open Access Publishing Group. All rights reserved.
This journal is a serial publication uniquely identified by an International Standard Serial Number (ISSN) serial number certificate issued by Romanian National Library. All the research works are uniquely identified by a CrossRef DOI digital object identifier supplied by indexing and repository platforms. All the research works published on this journal are meeting the Open Access Publishing requirements and standards formulated by Budapest Open Access Initiative (2002), the Bethesda Statement on Open Access Publishing (2003) and Berlin Declaration on Open Access to Knowledge in the Sciences and Humanities (2003) and can be freely accessed, shared, modified, distributed and used in educational, commercial and non-commercial purposes under a Creative Commons Attribution 4.0 International License. Copyrights of the published research works are retained by authors.
